Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 3.91% is 40% below its 5-year average of 6.55%, near the low end of its 5-year range (0.29%–25.46%).
14.03% below its 12-month average of 4.55%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 6.72%.
EBITDA MARGIN
3.91%
EBITDA MARGIN AVG TTM
4.55%
EBITDA MARGIN AVG 3Y
5.70%
EBITDA MARGIN AVG 5Y
6.55%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-14.03%
CURRENT VS 3Y AVG
-31.41%
CURRENT VS 5Y AVG
-40.27%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$1.87B
EBITDA Margin
-864.28%
TTM Avg
-1007.63%
3Y Avg
-1530.50%
5Y Avg
-1530.50%
Market Cap
$1.78B
EBITDA Margin
-695.72%
TTM Avg
-791.65%
3Y Avg
-791.65%
5Y Avg
-791.65%
Market Cap
$1.78B
EBITDA Margin
-628.14%
TTM Avg
-766.74%
3Y Avg
-948.44%
5Y Avg
-801.32%
Market Cap
$1.89B
EBITDA Margin
3.75%
TTM Avg
2.81%
3Y Avg
-0.66%
5Y Avg
-2.07%
Market Cap
$1.76B
EBITDA Margin
1.15%
TTM Avg
-0.80%
3Y Avg
-3.79%
5Y Avg
-4.67%
Market Cap
$1.71B
EBITDA Margin
16.41%
TTM Avg
1.22%
3Y Avg
-1.65%
5Y Avg
4.31%
Market Cap
$1.95B
EBITDA Margin
-4034.86%
TTM Avg
-3070.57%
3Y Avg
-2386.79%
5Y Avg
-1872.66%
Market Cap
$1.96B
EBITDA Margin
-13.52%
TTM Avg
-19.53%
3Y Avg
-24.36%
5Y Avg
-23.78%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Astrana Health, Inc. (ASTH) | $1.83B | 3.91% | 4.55% | 5.70% | 6.55% |
| Agios Pharmaceuticals, Inc. (AGIO)vs › | $1.87B | -864.28% | -1007.63% | -1530.50% | -1530.50% |
| Generate Biomedicines, Inc. (GENB)vs › | $1.78B | -695.72% | -791.65% | -791.65% | -791.65% |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.78B | -628.14% | -766.74% | -948.44% | -801.32% |
| BioLife Solutions, Inc. (BLFS)vs › | $1.89B | 3.75% | 2.81% | -0.66% | -2.07% |
| Alignment Healthcare, Inc. (ALHC)vs › | $1.76B | 1.15% | -0.80% | -3.79% | -4.67% |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.71B | 16.41% | 1.22% | -1.65% | 4.31% |
| Absci Corporation (ABSI)vs › | $1.95B | -4034.86% | -3070.57% | -2386.79% | -1872.66% |
| Establishment Labs Holdings Inc. (ESTA)vs › | $1.96B | -13.52% | -19.53% | -24.36% | -23.78% |
| Azenta, Inc. (AZTA)vs › | $1.97B | 8.41% | 9.50% | 6.21% | 7.73% |
Gross Margin
9.2%
EBITDA Margin
3.9%
Operating Margin
2.6%
Net Margin
1.1%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 6.72% |
| 2026-03-31 | 4.56% |
| 2025-12-31 | 3.66% |
| 2025-09-30 | 3.64% |
| 2025-06-30 | 4.16% |
| 2025-03-31 | 4.42% |
| 2024-12-31 | 1.33% |
| 2024-09-30 | 7.46% |
| 2024-06-30 | 7.71% |
| 2024-03-31 | 8.71% |
| 2023-12-31 | 0.29% |
| 2023-09-30 | 12.46% |
| 2023-06-30 | 8.98% |
| 2023-03-31 | 7.91% |
| 2022-12-31 | 5.66% |
| 2022-09-30 | 17.30% |
| 2022-06-30 | 7.32% |
| 2022-03-31 | 11.62% |
| 2021-12-31 | 3.41% |
| 2021-09-30 | 25.46% |
| 2021-06-30 | 14.36% |
